Lifecore Biomedical, Inc.
LFCR
Positions held
Your positionsLFCR isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $243.73M | Enterprise value | $432.72M | Trailing P/E | — | Forward P/E | -8.24 |
| PEG | 2.66 | Price / book | -7.11 | Beta | 0.98 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 31.4% | Operating margin | 7.5% |
| Profit margin | -23.8% | ROE | — | ROA | — | Debt / equity | 9.72 |
| Current ratio | 3.49 | Free cash flow | — | Analyst recommendation | hold | Mean target | $6.28 |
| 52w high | $8.98 | 52w low | $3.63 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|
| Revenue | $34.2M | $23.2M | $31.1M | $36.4M | $35.2M |
| Op margin | 7.5% | -20.1% | -9.9% | 8.0% | -6.2% |
| Net income | -$6.2M | -$15.0M | -$10.0M | -$1.1M | -$14.8M |
| Gross margin | 35.3% | 19.2% | 25.0% | 38.4% | 28.0% |
| Gross profit | $12.1M | $4.5M | $7.8M | $14.0M | $9.8M |
| Operating income | $2.6M | -$4.7M | -$3.1M | $2.9M | -$2.2M |
- Revenue +47% vs prior quarter ($34M vs $23M).
- Gross margin 35.3% (was 19.2% prior quarter).
- Operating margin expanded to 7.5%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $129M | $128M | $103M | $111M |
| Op margin | -9.3% | -5.6% | -19.1% | -3.1% |
| Net income | -$38.7M | $12.0M | -$99.6M | -$117M |
| Gross margin | 31.3% | 32.6% | 27.1% | 35.1% |
| Gross profit | $40.3M | $41.9M | $28.0M | $39.1M |
| Operating income | -$12.0M | -$7.2M | -$19.7M | -$3.4M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Lifecore Biomedical to Participate at Upcoming Industry Conferences
2026-09-29 · Lifecore Extends Manufacturing Contract With Alcon Research
2026-09-29 · Barrington Downgrades Lifecore Biomedical to Market Perform From Outperform, Removes $6.25 Price Target
2026-09-29 · Craig-Hallum Downgrades Lifecore Biomedical to Hold From Buy, Adjusts PT to $6.28 From $9
2026-09-29 · William Blair Downgrades Lifecore Biomedical to Market Perform From Outperform
2026-09-28 · Top Midday Gainers
2026-09-28 · Lifecore Biomedical to Be Acquired by Webster Equity Partners for Up to $663 Million
2026-09-28 · Lifecore Biomedical to be Acquired by Webster Equity Partners
2026-09-03 · Lifecore Biomedical to Participate at CPHI Global Conference
2026-09-02 · Lifecore Biomedical Signs Agreement for Commercial Site Transfer Supporting Global Pharmaceutical Company
2026-08-17 · Core Thesis Behind Lifecore Biomedical (LFCR): Monetizing Excess Capacity
2026-08-12 · Lifecore Biomedical (LFCR) Q2 2026 Earnings Call Transcript
Price (daily)
Full chart · RSI · MACD · patterns